Aptose Biosciences Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Product Pipeline
    • Overview
    • Tuspetinib for AML
    • Luxeptinib for B-cell Tumors
    • Luxeptinib for Myeloid Tumors
    • Posters & Presentations
  • Clinical Trials
    • Overview
    • Luxeptinib for CLL & NHL
    • Luxeptinib for AML
    • Tuspetinib for AML
    • Expanded Access
  • News
    • Press Releases
    • Presentations
    • Events
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • SEDAR
    • Governance
  • Join Us
    • Values & Culture
    • Perks & Benefits
    • Explore Careers
  • Contact

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Cash Flow
  • Stock Data
    • TSX: APS
    • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • SEDAR
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts

Aptose’s New “G3” Formulation of Luxeptinib Boosts Bioavailability

Sep 12, 2022 7:30am EDT

Aptose to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Aug 30, 2022 7:30am EDT

Aptose Reports Results for the Second Quarter 2022

Aug 02, 2022 4:01pm EDT

Aptose to Present at the Canaccord Genuity 42nd Annual Growth Conference

Jul 27, 2022 7:30am EDT

Aptose to Report Second Quarter 2022 Financial Results and Hold Conference Call on Tuesday, August 2, 2022

Jul 19, 2022 4:01pm EDT

Aptose Appoints Fletcher Payne as Senior Vice President, Chief Financial Officer

Jun 27, 2022 7:30am EDT

Aptose Presents Highlights from Corporate Update and KOL Event

Jun 02, 2022 8:10pm EDT

Aptose Biosciences Announces Results of Annual Meeting of Shareholders

May 31, 2022 4:15pm EDT

Aptose to Provide Program Updates at KOL Webinar on Thursday, June 2nd

May 25, 2022 8:30am EDT

Aptose to Hold KOL Event and Corporate Update Thursday, June 2nd

May 12, 2022 10:00am EDT
RSS
  • Prev
    • 1...
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • 11
    • 12
    • 13
    • ...32
    Next
    • Email Alerts
    • Contacts
    • RSS News Feed
    © 2025 Aptose Biosciences Inc. All Rights Reserved.
    Privacy Policy Clinical Trials Policy Disclaimer Sitemap Manage Cookie Preferences